TORONTO–(BUSINESS WIRE)–High Park Holdings Ltd. (“High Park”), a wholly-owned subsidiary of Tilray, Inc. (NASDAQ: TLRY), today announced the newest addition to its cannabis-infused edible product line: Chowie Wowie Gummies, which are now available in select provinces across Canada.
Chowie Wowie Gummies are available in two delicious flavours:
● THC Watermelon Gummies (2.5mg THC per gummy)
● Balanced THC/CBD Pineapple Mango Gummies (2.5mg THC, 2.5mg CBD per gummy)
Product highlights include:
● Clean Ingredients: Chowie Wowie Gummies are handcrafted using clean and simple ingredients. Leveraging a pectin base, our gummies are vegan and gluten free with a delicious taste profile;
● 100 percent Distillate: Made with 100 percent distillate to ensure delicious taste and aroma with minimal cannabis flavour;
● Four Per Pack: Four gummies per pack provides the perfect format for dosing and sharing; and
● Affordable Price: $6.99 MSRP.
Chowe Wowie Gummies began to roll into the market during the week of September 28, 2020, in select provinces across Canada, including Alberta, British Columbia, Manitoba, Saskatchewan, Ontario and New Brunswick. Consumers can look for product offerings to expand later in 2020, with the addition of a THC Sour Cherry (2.5mg THC) flavoured gummy in the near future.
High Park Portfolio of Brands
High Park’s portfolio of brands also includes offerings from Irisa™, Grail™, The Batch™, Dubon™ and Yukon Rove™. High Park forward to continuing to refine, expand and roll-out robust offerings of unique brands and innovative products to consumers across Canada to meet the needs of this growing industry.
High Park Quality Standards
High Park is proud to offer consumers a variety of product formats to meet varying needs and preferences. All products adhere to Health Canada’s rigorous standards for safety and quality. All-in-one-vape pens and cartridges contain pure, GPP (Good Production Practices)-produced cannabis oil with no additives, and do not contain carrier oils, diluents, Vitamin E acetate or flavours. All product formulations and hardware are rigorously tested to ensure quality and purity for consumer use.
Forward Looking Statements
This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements regarding our growth potential, the sustainability of growth, the optimization of our facilities and estimated net savings, our ability to become Adjusted EBITDA positive by the end of 2020, demand, viability and development of our specific products and the medical and Adult Use cannabis markets generally, medicinal regulatory approvals and clinical trials, anticipated plans for strategic partnerships and acquisitions, and future sales of our common stock. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on August 10, 2020, and subsequent periodic reports, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.